Thermo Fisher to collaborate with Torque to develop Slipstream™
Category: #health  By Mateen Dalal  Date: 2019-02-05
  • share
  • Twitter
  • Facebook
  • LinkedIn

Thermo Fisher to collaborate with Torque to develop Slipstream™

The Torque-Thermo Fisher manufacturing facility is expected to come online by the end of 2019.

Thermo Fisher Scientific Inc., the biotechnology products development company and Torque, an immuno-oncology company recently announced that they will be collaborating to develop Slipstream™, which is a high efficiency T cell manufacturing facility, developed by Torque. The facility is important for expanding the cellular immunotherapy pipeline of Torque and its development of Deep Primed™ T Cell Therapeutics which is designed to direct immune power found within the microenvironment of the tumor itself.

BioSpectrum reports that Torque-Thermo Fisher manufacturing facility is already under construction and is anticipated to be processing patient cells by end of 2019. Reportedly, Torque's main Deep-Primed T cell candidate, TRQ-1501, will be the first to experience clinical development within the Slipstream platform.

Bart Henderson, CEO, Torque has been quoted to say that the cell manufacturing technology platform is critical in developing and commercializing cellular immunotherapy for patients in initial or advanced stages of cancer. This would be particularly beneficial for solid tumor patients who are in need of such a treatment. He added that Torque is looking forward to collaborating with Thermo Fisher as the company is renowned for its track record in building globally integrated, high-efficiency operations.

Henderson elaborated on the platform’s potential of benefiting a significant population of cancer patients and said that the pioneering manufacturing partnership is aimed at drastically enhancing the efficacy and scalability of best-in-class cellular immunotherapy production.

Michel Lagarde, President, Pharma Services, Thermo Fisher Scientific has been reported to say that Thermo Fisher in collaboration with Torque would be posing an instance of the progress it has made in its dedication to advancing precision medicine and becoming a leader in cell therapy manufacturing. He expressed Thermo Fisher’s pleasure in the partnership in building the Slipstream technology based advanced manufacturing facility, that is meant to transform cancer treatment.

For the record, the Slipstream platform technology is located in Princeton and is a groundbreaking design that involves the use of a semi-automated, fully closed system that beats conventional cell therapy manufacturing methods. A substantially smaller manufacturing footprint as well as less labor-intensive and costly method is involved in the Slipstream process, all of which work as its chief leverage.

  • share
  • Twitter
  • Facebook
  • LinkedIn


About Author

Mateen Dalal    

Mateen Dalal

A qualified electronics and telecommunication engineer, Mateen Dalal embarked on his professional journey working as a quality and test engineer. Harnessing his passion for content creation however, Mateen pens down industry-rich articles for ReportsGO.com and a few o...

Read More

More News By Mateen Dalal

Merck to acquire cancer drug maker Peloton Therapeutics for $1.05Bn
Merck to acquire cancer drug maker Peloton Therapeutics for $1.05Bn
By Mateen Dalal

The acquisition would help Merck strengthen its presence in the renal cell carcinoma space and support its cancer drug portfolio. U.S. pharmaceutical conglomerate, Merck & Co. Inc. has recently agreed to purchase Dallas based Peloton Therapeutic...

Ikea invests in India’s one-stop interior design platform Livspace
Ikea invests in India’s one-stop interior design platform Livspace
By Mateen Dalal

The interior design platform had raised over $70 million last year with investment from TPG Growth & Goldman Sachs. The investment is Ikea’s first such deal in India, however it isn’t the company’s dalliance in India’s ...

BioXcel unveils data from Phase 1 study of receptor agonist BXCL501
BioXcel unveils data from Phase 1 study of receptor agonist BXCL501
By Mateen Dalal

Sublingual administration of BXCL501 had achieved drug exposures that will be therapeutic for the acute treatment of agitation Reports confirm that BioXcel Therapeutics (BTI) has recently presented data from its Phase 1 pharmacokinetic (bioavailabil...